Details of the Drug
General Information of Drug (ID: DMN72OM)
Drug Name |
U300
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Methyl 3,5-dinitrobenzoate; 2702-58-1; Benzoic acid, 3,5-dinitro-, methyl ester; POGCCFLNFPIIGW-UHFFFAOYSA-N; 3,5-dinitro-benzoic acid methyl ester; Methyl 3,5-Dinitrobenzoate,99%; Methyl-3,5-dinitrobenzoate; U300; ACMC-1CR6Q; AC1L5B8W; AC1Q5AI0; KSC494Q3H; SCHEMBL418416; Jsp005266; CHEMBL2252127; CTK3J4833; KS-00000ZZJ; NSC7317; MolPort-001-012-121; Methyl 3,5-dinitrobenzoate, 99%; ALBB-024845; NSC-7317; ZINC1683476; METHYL-3,5-DINITRO BENZOATE; BBL000013; ANW-44565; SBB068882; MFCD00017016; STK386186; 3,5-Dinitrobenzoic acid methyl e
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 226.14 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.8 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 6 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Type-2 diabetes | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | 5A11 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||